The all-stock deal, paired with a $200 million raise, hands Processa a once-daily, brain-penetrating BTK inhibitor targeting food allergy, chronic urticaria and multiple sclerosis.
One brain-age number hides where the aging is. Down to the voxel, the frontal and temporal lobes look older — and in Alzheimer’s, the hippocampus looks oldest.
Antibodies work outside cells. The proteins that cause Alzheimer’s, Parkinson’s and Huntington’s do their damage inside them. Getting the electrical charge right turned out to be the key.
APOE4 raises Alzheimer’s risk and nobody could say how. Gladstone researchers found it drives one protein up inside neurons — and lowering that protein in adult mice reversed the damage.
Medigen already sells an EV71 vaccine in Taiwan and Vietnam. Broadening it to cover more enterovirus strains is the harder problem — and Charles River supplies the machinery for proving it.
Autopsy data from thousands of women: 18% of hormone therapy users showed no Alzheimer’s pathology versus 10% of non-users. The women studied started therapy around 70, not 50 — which matters enormously.
COPD drugs open airways or damp inflammation broadly. A DPP1 inhibitor switches off the enzyme that arms the destructive enzymes in the first place.
Two mechanisms in one tablet, beating either alone across eight studies — and doubling the ways to exceed a safe dose without noticing.
A fish bred without one collagen gene developed a human spinal disease — and two drugs already on pharmacy shelves slowed it down.
The money arrives only when the FDA accepts the filing. Milestone-linked financing lets a biotech raise at tomorrow’s valuation rather than today’s — if tomorrow arrives.
One base inserted, one protein gone, no foreign DNA. Two beagles that people allergic to dogs did not react to — and a set of questions the field has not answered.
Silencing a gene without cutting it. Scribe’s bet is that reversibility beats permanence — and $129 million is a cautious vote for the sector.